Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Center for Network Therapy Medical Director Says Opioid Prescription Decline Data Misleading; Heroin And Fentanyl Still Driving Opioid Overdose Deaths Higher
  • USA - English


News provided by

Center for Network Therapy

Jul 07, 2017, 14:15 ET

Share this article

Share toX

Share this article

Share toX


New York, NY (PRWEB) July 07, 2017 -- Opioid prescription data released this week by the Centers for Disease Control and Prevention (CDC) revealed the number of opioid pain pill prescriptions per 100 people declined by 13% and the potency declined by 41% in the 2010-2015 period. While the drop in prescriptions is encouraging, the reality is sobering and points to more people switching to street drugs, according to Addiction Expert Dr. Indra Cidambi, Founder and Medical Director of the Center for Network Therapy.

“Seasoned users of prescription pain pills have likely left the system, as it cheaper to obtain illicit opiates on the street,” said Dr. Cidambi.

Post this

“Due to tighter oversight of opioid prescriptions and sharp decline in prices of illegal opioids (heroin and fentanyl) individuals addicted to opiates have been switching to street drugs.” Overdose deaths from opiates have risen every year starting in 1999. In the 2010-2015 period, overdose deaths from all opiates (licit + Illicit) grew an astounding 57% to 33,000 in 2015 (NIDA), despite a plateauing of overdose deaths from prescription opioid pain relievers (licit).

As per this week’s CDC Report:
• The annual opioid medication prescribing rate by doctors dropped 13 percent, from 81 prescriptions per 100 people to 71 prescriptions per 100 people.
• Doctors also prescribed high doses of opioids less often - high-dose prescriptions fell 41 percent, from 11.4 per 100 people to 6.7 per 100 people.
• The length of prescriptions increased from an average of 13 days in 2006 to 18 days in 2015.
The Drug Enforcement Administration and state and local governments have increased oversight of opiate pain medication prescriptions in some shape or form over the years, which has definitely contributed to the decline in the rate of prescriptions. “Consequently, individuals addicted to pain pills have had a harder time accessing opiate pain pills through their medical care providers,” said Dr. Cidambi. “The reality on the street, however, is that heroin and synthetic opiates are cheaper to obtain, causing individuals addicted to opiate pain pills to switch to these street drugs.”

“Seasoned users of prescription pain pills have likely left the system, as it is cheaper to obtain illicit opiates on the street,” said Dr. Cidambi. “These individuals had likely developed tolerance for the drug and were being prescribed higher-potency doses previously.” Consequently, a sharp decline in high-dose prescriptions may be due to this ongoing switch.

“Individuals who seek prescriptions for opiate pain pills to feed their addiction usually indulge in doctor shopping,” said Dr. Cidambi. “It is not uncommon for them to visit multiple doctors just once in a short period of time to obtain prescriptions, sometimes crossing state lines. As illicit opiates have become much cheaper, they now have no reason to doctor shop,” adds Dr. Cidambi. This may have contributed to the lengthening of prescriptions.

According to Dr. Cidambi, the opioid prescription decline data is an isolated piece of information that is not connected to the whole and is misleading. While the nation is weary of the fight against the drug epidemic and is ready to welcome any positive news with open arms, it is still too premature to think that we have turned the corner in this fight. “The fight against this epidemic has to be multi-faceted. As a nation, we need to work on removing the stigma from addiction and recognize that it is a disease. Just coercing doctors to write lesser opiate pain prescriptions is not the panacea,” said Dr. Cidambi.

Dr. Cidambi recommends the following courses of action to help fight the opioid epidemic:
• To address pain, health insurance companies should be mandated to cover alternate treatment (acupuncture, meditation, yoga, etc.) along with physical therapy and non-narcotic pain medications.
• When it comes to treatment, modalities that help the patient remain sober in their own environment (outpatient treatment, such as Ambulatory Detoxification) should be supported as they can deliver better outcomes. Inpatient treatment has so far been dominant, but ineffectual in the face of this epidemic. I have been treating individuals afflicted by addiction for over a decade and I strongly believe the best rehabilitation takes place at home, not in a bubble far from the individual’s real living environment. These individuals not only need to learn coping and relapse prevention skills, they need to practice using it and they benefit from the opportunity to apply it in the real world while they are in treatment.
• Another important issue is reintegrating these individuals back into the work force. Charges incurred while they were using substances hang over their head when they get sober and try to put their lives back together. Decriminalization utilizing token-economy (dropping charges if the individual completes treatment and stays sober for a certain period of time) provides the individual afflicted by the disease of addiction an incentive to seek treatment and embark on the road to recovery.
About Dr. Indra Cidambi
Indra Cidambi, M.D., Medical Director, Center for Network Therapy, is recognized as a leading expert and pioneer in the field of Addiction Medicine. Under her leadership the Center for Network Therapy started New Jersey’s first state licensed Ambulatory (Outpatient) Detoxification program for all substances nearly three years ago. Dr. Cidambi is Board Certified in General Psychiatry and double Board Certified in Addiction Medicine (ABAM, ABPN). Dr. Cidambi is the Vice President of the New Jersey Society of Addiction Medicine. She is fluent in five languages, including Russian.

About Center for Network Therapy
Center for Network Therapy (CNT) was the first facility in New Jersey to be licensed to provide Ambulatory (Outpatient) Detoxification Services for all substances of abuse – alcohol, anesthetics, benzodiazepines, opiates and other substances of abuse. Led by a Board Certified Addiction Psychiatrist, Indra Cidambi, M.D., experienced physicians and nurses closely monitor each patient’s progress. With CNT’s superior client care and high quality treatment, Dr. Cidambi and her clinical team have successfully detoxed over 1200 patients in four years.

Marisa Amador, Center for Network Therapy, +1 212.805.3029, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.